Clusters of Human Infection and Human-to-Human Transmission of Avian Influenza A(H7N9) Virus, 2013–2017

Lei Zhou,1 Enfu Chen,1 Changjun Bao,1 Nijuan Xiang,1 Jiabing Wu, Shengen Wu, Jian Shi, Xianjun Wang, Yaxu Zheng, Yi Zhang, Ruiqi Ren, Carolyn M. Greene, Fiona Havers, A. Danielle Iuliano, Ying Song, Chao Li, Tao Chen, Yali Wang, Dan Li, Daxin Ni, Yanping Zhang, Zijian Feng, Timothy M. Uyeki, Qun Li

Author affiliations: Public Health Emergency Center of the Chinese Center for Disease Control and Prevention, Beijing, China (L. Zhou, N. Xiang, R. Ren, Y. Wang, D. Li, D. Ni, Y. Zheng, Z. Feng, Q. Li); Zhejiang Center for Disease Control and Prevention, Hangzhou, China (E. Chen); Jiangsu Center for Disease Control and Prevention, Nanjing, China (C. Bao); Anhui Center for Disease Control and Prevention, Hefei, China (J. Wu); Fujian Center for Disease Control and Prevention, Fuzhou, China (S. Wu); Hebei Center for Disease Control and Prevention, Shijiazhuang, China (J. Shi); Shandong Center for Disease Control and Prevention, Jinan, China (X. Wang); Shanghai Center for Disease Control and Prevention, Shanghai, China (Y. Zheng); Shaanxi Center for Disease Control and Prevention, Xi’an, China (Y. Zhang); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.M. Greene, F. Havers, A.D. Iuliano, Y. Song, T.M. Uyeki); National Influenza Center of the Chinese Center for Disease Control and Prevention, Beijing (T. Chen); Chinese Center for Disease Control and Prevention, Beijing (Z. Feng)

DOI: https://doi.org/10.3201/eid2402.171565

To detect changes in human-to-human transmission of influenza A(H7N9) virus, we analyzed characteristics of 40 clusters of case-patients during 5 epidemics in China in 2013–2017. Similarities in number and size of clusters and proportion of clusters with probable human-to-human transmission across all epidemics suggest no change in human-to-human transmission risk.

Since December 2016, the number of human infections with avian influenza A(H7N9) virus in China has increased markedly (1,2), prompting concerns of pandemic influenza. Early signals of greater human-to-human transmissibility might be increased number and size of clusters of epidemiologically linked human infections and clusters of case-patients who are not blood relatives or increased numbers of case-patients with mild illness (3). To elucidate whether the increase in human infections during the fifth epidemic (2016–2017) in China was associated with increased human-to-human transmissibility of A(H7N9) virus, we compared the characteristics of clusters of A(H7N9) case-patients during the fifth epidemic with those of clusters of case-patients identified from the previous 4 epidemics (2013–2016).

The Study

For each laboratory-confirmed A(H7N9) virus infection reported in mainland China, the provincial or local Center for Disease Control and Prevention (CDC) initiated a field investigation to monitor close contacts for illness signs and symptoms for 10 days after the last known exposure to a symptomatic index case-patient (3). Upper respiratory specimens collected from close contacts with respiratory symptoms were tested for A(H7N9) virus as previously described (3). Detailed information (e.g., demographic data, household and family relationships, exposures to index case-patients and poultry, and clinical management and outcomes) was collected from case-patients, close contacts with laboratory-confirmed A(H7N9) virus infection, and their close contacts. Collection and analyses of data from case-patients with influenza A(H7N9) virus infection were part of an ongoing public health investigation of emerging outbreaks and were exempt from institutional review board assessment in China (2).

An epidemic period was defined as September 1 through August 31 of the following year. A cluster was defined as ≥2 epidemiologically linked case-patients with laboratory-confirmed A(H7N9) virus infection and illness onset within 10 days of each other. Within clusters, probable human-to-human transmission was defined as occurrence of secondary infection in a person who had close contact with a symptomatic index case-patient but no known poultry exposure; possible human-to-human transmission was defined as occurrence of secondary infection in a person who had close contact with a symptomatic index case-patient and known poultry exposure.

We performed descriptive analyses of laboratory-confirmed A(H7N9) case-patient data reported to the China CDC during February 1, 2013–June 30, 2017. We described the number of clusters per epidemic period and compared cluster patient characteristics from the fifth epidemic with those from previous epidemics; specifically, we compared numbers of clusters; case-patients per cluster; and case-patient age, sex, underlying medical conditions, hospitalization, oseltamivir treatment, intensive care unit admission, invasive mechanical ventilation, and deaths. We compared the characteristics of sporadic (noncluster) case-patients with those of index and secondary case-patients; in clusters with...
probable human-to-human transmission, we also compared index with secondary case-patients. Because of our interest in human-to-human transmission, we focused our analyses on clusters in which secondary case-patients reported no exposure to poultry. We compared categorical variables by using \( \chi^2 \) or Fisher exact tests and median ages by using the rank-sum Wilcoxon test. All tests of statistical significance were 2-sided with a cutoff of \( p = 0.05 \).

As of June 30, 2017, we identified 84 infections comprising 40 clusters among 1,524 A(H7N9) case-patients reported since February 2013 (Table). Most clusters were located in southern and eastern China (online Technical Appendix Figure, https://wwwnc.cdc.gov/EID/article/24/2/17-1565-Techapp1.pdf). We identified 14 clusters in the fifth epidemic, compared with 4–11 clusters in prior epidemics. The 14 clusters in the fifth epidemic comprised 29 human infections; previous epidemics had clusters of 8–23 human infections per epidemic. In the fifth epidemic, 13 (93%) clusters had 2 infections each and 1 had 3 infections, compared with 23 (88%) clusters with 2 infections each and 3 clusters with 3 infections each among 26 clusters in epidemics 1–4. The proportion of all infections that occurred in clusters differed significantly among all clusters (\( p = 0.023 \)) and was lowest during the fifth epidemic (4%).

Among the 40 clusters for all 5 epidemics, we classified 14 (35%) as probable and 26 (65%) as possible human-to-human transmission. The proportion of clusters with probable human-to-human transmission only did not differ significantly by epidemic (\( p = 0.842 \)) (online Technical Appendix Table). A cluster of 3 infections in the fifth epidemic had possible and probable human-to-human transmission; 2 similar clusters were identified during the fourth epidemic. We identified no cluster with potential spread beyond 2 generations.

Among 14 secondary infections with probable human-to-human transmission during 2013–2017, we linked 4 to household exposures and 10 to exposures in healthcare settings, including 4 during the fifth epidemic. These 10 nosocomial infections included 3 blood relatives exposed to index case-patients (1 each in the second, fourth, and fifth epidemics); 1 unrelated household member exposed to an index case-patient in the second epidemic; and 6 unrelated patients exposed to index case-patients (1 each in the second, third, and fourth epidemics and 3 in the fifth epidemic).

### Table. Features of sporadic and clusters of human infections with avian influenza A(H7N9) virus, mainland China, February 1, 2013–June 30, 2017*

| Category                          | Total       | First  | Second | Third  | Fourth | Fifth  |
|-----------------------------------|-------------|--------|--------|--------|--------|--------|
| Overall infections                |             |        |        |        |        |        |
| Infections, no.                   | 1,524       | 134    | 304    | 219    | 118    | 749    |
| Deaths, no. (%)                   | 599 (39.3)  | 44 (32.8) | 126 (41.4) | 99 (45.2) | 47 (39.8) | 283 (37.8) |
| Sporadic infections†              |             |        |        |        |        |        |
| Infections, no.                   | 1,440       | 126    | 281    | 207    | 106    | 720    |
| Deaths, no. (%)                   | 570 (39.6)  | 39 (31.0) | 120 (42.7) | 94 (45.4) | 45 (42.5) | 272 (37.8) |
| Cluster infections                |             |        |        |        |        |        |
| Infections, no. (%)               | 84 (5.5)    | 8 (6.0) | 23 (7.6) | 12 (5.5) | 12 (10.2) | 29 (3.9) |
| Deaths, no. (%)                   | 29 (34.5)   | 5 (62.5) | 6 (26.1) | 5 (41.7) | 2 (16.7) | 11 (37.9) |
| All clusters                      |             |        |        |        |        |        |
| Clusters, no.                     | 40          | 4      | 11     | 6      | 5      | 14     |
| Clusters with 2 infections, no.   | 36          | 4      | 10     | 6      | 3      | 13     |
| Clusters with 3 infections, no.   | 4           | 0      | 1      | 0      | 2      | 1      |
| Deaths of index case-patients, no. (%)| 19 (46.3) | 3 (75.0) | 5 (45.5) | 2 (33.3) | 1 (16.7) | 8 (57.1) |
| Deaths of secondary case-patients, no. (%)| 10 (23.3) | 2 (50.0) | 1 (8.3) | 3 (50.0) | 1 (16.7) | 3 (20.0) |
| Clusters with probable human-to-human transmission only | | | | | | |
| Clusters, no. (%)                 | 11 (30.0)   | 2 (50.0) | 3 (27.3) | 2 (33.3) | 1 (20.0) | 3 (21.4) |
| Clusters with 2 infections, no.   | 11          | 2      | 3      | 2      | 1      | 3      |
| Clusters with 3 infections, no.   | 0           | 0      | 0      | 0      | 0      | 0      |
| Infections, no.                   | 22          | 4      | 6      | 4      | 2      | 6      |
| Index, no.                        | 11          | 2      | 3      | 2      | 1      | 3      |
| Secondary, no.                    | 11          | 2      | 3      | 2      | 1      | 3      |
| Blood-related family members      | 12          | 4      | 2      | 2      | 2      | 2      |
| Unrelated persons                 | 10          | 0      | 4      | 2      | 0      | 4      |
| Overall deaths, no. (%)           | 12 (54.5)   | 3 (75.0) | 3 (50.0) | 2 (50.0) | 1 (50.0) | 3 (50.0) |
| Of index case-patients, no. (%)   | 9 (81.8)    | 2 (100.0) | 6 (66.7) | 1 (50.0) | 1 (100.0) | 3 (100.0) |
| Of secondary case-patients, no. (%)| 3 (27.3)   | 1 (50.0) | 1 (33.3) | 1 (50.0) | 0      | 0      |

*Categorical variables among the 5 epidemics were compared by using \( \chi^2 \) or Fisher exact tests. Median age was compared by Wilcoxon test. The proportion of infections in clusters was lowest for the fifth epidemic; the proportion of infections in clusters per epidemic differed significantly during 2013–2017 (\( \chi^2 = 11.30; p = 0.023 \)). The remaining items did not differ significantly among the 5 epidemics. The reporting of deaths may be delayed; therefore, these numbers may change as additional deaths are confirmed.

†The first epidemic was defined as February through August 31, 2013; each subsequent epidemic was defined as September 1 through August 31 of the following year.

‡Excludes human infections that were identified in clusters.
Clusters of probable limited human-to-human A(H7N9) virus infections, including in healthcare settings, underscore the value of adhering to recommended infection prevention and control measures to prevent nosocomial A(H7N9) virus transmission (5–8). Ongoing assessment of the epidemiology of human infections with avian influenza A(H7N9) virus to identify any increase in human-to-human transmission will inform pandemic risk assessment, preparedness, and response (9).

Acknowledgments
We thank staff in the local and provincial CDCs in China, especially Guangdong, Hunan, Jiangxi, Sichuan, Tibet, Yunnan, Inner Mongolia, and Beijing provincial CDCs, for providing assistance with data collection. We also thank Yuelong Shu and colleagues at the Chinese National Influenza Center for their contributions to laboratory testing.

This work was supported by the Ministry of Science and Technology of China, Emergency Technology Research Issue on Prevention and Control for Human Infection with A(H7N9) Avian Influenza Virus (KJYJ-2013-01-02) and the China–US Collaborative Program on Emerging and Re-emerging Infectious Diseases, and National Mega-projects for Infectious Diseases (2014ZX10004002-002-004), and Emergency Technology Research Issue on Prevention and Control for Human Infection with A(H7N9) Avian Influenza Virus (KJYJ-2017-01-06).

About the Author
Dr. Zhou is deputy chief of the Branch for Emerging Infectious Diseases, Public Health Emergency Center, China CDC. Her research interests are prevention and control of emerging infectious diseases and pandemic influenza preparedness and response.

References
1. Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, et al. Update: increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic—China, October 1, 2016–August 7, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:928–32. http://dx.doi.org/10.15585/mmwr.mm6635a2
2. Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017;17:822–32. http://dx.doi.org/10.1016/S1473-3099(17)30323-7
3. Uyeki TM, Bresee JS. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13:1969–71. http://dx.doi.org/10.3201/eid1312.071153
4. Chen Z, Liu H, Lu J, Luo L, Li K, Liu Y, et al. Asymptomatic, mild, and severe influenza A(H7N9) virus infection in humans, Guangzhou, China. Emerg Infect Dis. 2014;20:1535–40. http://dx.doi.org/10.3201/eid2009.140424
5. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med. 2014;370:520–32. http://dx.doi.org/10.1056/NEJMoa1304617

Conclusions
Despite the surge in human infections with A(H7N9) virus during the fifth epidemic in China, the similarity in number and size of clusters and proportions of clusters with probable human-to-human transmission during 2013–2017 suggest no change in human-to-human A(H7N9) virus transmission risk over time. These findings suggest that the increase in human infections during the fifth epidemic probably reflects an increase in sporadic poultry-to-human A(H7N9) virus transmission over a wide geographic area in China (1).

Although we restricted the assessment of human-to-human A(H7N9) virus transmission in probable clusters to secondary case-patients without identified poultry exposure, we may have overestimated human-to-human transmission in clusters if not all poultry exposures were identified and reported. We could have underestimated human-to-human transmission by excluding infections in possible clusters with exposures to both poultry and symptomatic case-patients. Only symptomatic close contacts of index case-patients were tested, possibly underestimating the size of clusters of patients with asymptomatic infections (4).
Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017

Xinyu Wang, Qiuling Ruan, Bin Xu, Jianfei Gu, Yiyi Qian, Muxin Chen, Qin Liu, Qing Lu, Wenhong Zhang

Human African trypanosomiasis is endemic to parts of sub-Saharan Africa and should be considered in the differential diagnosis of patients who have visited or lived in Africa. We report a 2017 case of stage 2 Trypanosoma brucei gambiense disease in an emigrant who returned to China from Gabon.

Human African trypanosomiasis (HAT), or sleeping sickness, is a tsetse fly–borne parasitic disease that is endemic to parts of sub-Saharan Africa. In central and west Africa, Trypanosoma brucei gambiense causes the slow-progressing form of the disease, and T. brucei rhodesiense causes the fast-progressing form in east and southern Africa (I). We report a confirmed case of HAT, after a probable tsetse fly bite, in a man who returned to China from Gabon in central Africa.

A previously healthy 60-year-old man from China lived in Gabon for 8 years. He served as a seaman and traveled between Libreville and Kango to transport river sand. In July 2016, when he was working on a rural farm in Libreville, he had a painful, unidentified insect bite on his right lower limb. The bite wound developed into an indurated, erythematous, and painful skin lesion. He received antiviral and antityphoid therapy in Gabon. Although the skin lesion healed, he had intermittent fever (up to 40°C), headache, and fatigue.

He returned to Jiangshu, China, for further treatment in June 2017. Magnetic resonance imaging (MRI) of the brain revealed temporal foci suggestive of white matter demyelination. Brain magnetic resonance angiography and encephalography revealed normal findings. He had daytime somnolence 2 weeks before admission to Huashan Hospital, associated with Fudan University in Shanghai, on August 30. The patient was lethargic during admission and had a temperature of 38.5°C and palpable cervical and inguinal lymph nodes. Hyperpigmentation of the right lower limb was visible. Meningeal irritation and the Babinski sign were absent.

The preliminary diagnosis was suspected HAT. We performed bone marrow puncture, which revealed a few trypanomastigotes (Trypanosoma spp.; Figure 1, panel A). We also found trypanosomes in a peripheral blood smear. We sent a serum sample to the Chinese Center for Disease Control and Prevention (China CDC), which showed a positive result for the T. brucei gambiense antibody test. A cerebrospinal fluid (CSF) sample revealed an open pressure of 15 cm H₂O, a leukocyte count of 9 cells/μL, a protein level of 1,412 mg/dL, and a glucose level of 1.6 mmol/L. Direct examination revealed no trypanosomes in the CSF, although next-generation sequencing identified T. brucei gambiense in the CSF and bone marrow (stage 2 disease). Brain MRI revealed hyperintense signal changes in the left basal ganglia, and positron emission tomography–computed tomography suggested reduced glucose metabolism (Figure 1, panels B, C). The World Health Organization (WHO) and China CDC helped obtain nifurtimox and eflornithine, which we administered to the patient within 48 h after the diagnosis. The patient was discharged after 10 days of treatment.

Several HAT cases had previously been imported into China. One case-patient was a 45-year-old man who worked in forests and river valleys in Gabon and was diagnosed with T. brucei gambiense disease by blood smear in 2014, two months after returning to China (2). The second case involved a woman, 41 years of age, who traveled to Tanzania and Kenya, and was diagnosed with T. brucei rhodesiense by blood smear in 2017, one week after returning to China. Both cases were confirmed by molecular
Clusters of Human Infection and Human-to-Human Transmission of Influenza A(H7N9) Virus, China, 2013–2017

Technical Appendix

**Technical Appendix Table.** Comparison of illness severity in clusters of human infections with avian influenza A(H7N9) virus in mainland China, February 1, 2013 - June 30, 2017*

| Characteristics | Comparison of sporadic and cluster-associated index infections | Comparison of cluster-associated index and secondary infections with probable human-to-human transmission |
|-----------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
|                 | Sporadic infections | Index infections | P value | Index infections | Secondary infections† | P value |
| Total No. of infections | First epidemic | 126 | 2 | – | 2 | 2 | – |
|                     | Second epidemic | 281 | 3 | – | 3 | 3 | – |
|                     | Third epidemic | 207 | 2 | – | 2 | 2 | – |
|                     | Fourth epidemic | 106 | 4 | – | 4 | 3 | – |
|                     | Fifth epidemic | 720 | 4 | – | 4 | 4 | – |
|                     | Total | 1,440 | 15 | – | 15 | 14 | – |
| Median age (range), years | First epidemic | 62 (2–91) | 74 (61–87) | 0.257 | 74 (61–87) | 51 (33–68) | 0.699 |
|                     | Second epidemic | 58 (2–88) | 57 (57–60) | 0.955 | 57 (57–60) | 33 (30–70) | 0.658 |
|                     | Third epidemic | 56 (1–88) | 54 (48–59) | 0.796 | 54 (48–59) | 29 (1–57) | 0.699 |
|                     | Fourth epidemic | 58 (14–91) | 28 (13–35) | 0.001 | 28 (13–35) | 68 (21–87) | 0.377 |
|                     | Fifth epidemic | 57 (3–92) | 64 (29–66) | 0.772 | 64 (29–66) | 62 (39–63) | 0.655 |
|                     | Total | 57 (1–92) | 57 (13–87) | 0.321 | 57 (13–87) | 60 (1–87) | 0.631 |
| Male, no. (%) | First epidemic | 88 (70) | 2 (100) | 1.000 | 1 (100) | 1 (50) | 1.000 |
|                 | Second epidemic | 198 (70) | 3 (100) | 0.558 | 3 (100) | 3 (100) | – |
| Characteristics                        | Comparison of sporadic and cluster-associated index infections | Comparison of cluster-associated index and secondary infections with probable human-to-human transmission |
|----------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
|                                        | Sporadic infections | Index infections | P value | Index infections | Secondary infections\* | P value |
| Total No. of infections                | 126                | 2               | –       | 2               | 2                   | –       |
| First epidemic                         |                    |                 |         |                 |                      |         |
| Third epidemic                         | 142 (69)           | 2 (100)         | 1.000   | 2 (100)         | 2 (100)             | –       |
| Fourth epidemic                        | 71 (67)            | 3 (75)          | 1.000   | 3 (75)          | 0 (0)               | 0.143   |
| Fifth epidemic                         | 551 (71)           | 4 (100)         | 0.582   | 4 (100)         | 2 (50)              | 0.429   |
| Total                                  | 1,014 (70)         | 14 (93)         | 0.082   | 14 (93)         | 8 (57)              | 0.035   |
| Underlying medical conditions, no. (%) | First epidemic     | 41/125 (33)     | 0.113   | 2 (100)         | 1 (50)              | 1.000   |
|                                        | Second epidemic    | 115/281 (41)    | 0.571   | 2 (67)          | 1 (33)              | 1.000   |
|                                        | Third epidemic     | 79/207 (38)     | 1.000   | 1 (50)          | 1 (50)              | 1.000   |
|                                        | Fourth epidemic    | 51/106 (48)     | 0.620   | 1 (25)          | 2 (40)              | 1.000   |
|                                        | Fifth epidemic     | 308/700 (44)    | 1.000   | 2 (50)          | 2 (50)              | 1.000   |
| Total                                  | 594/1,419 (42)     | 8 (53)          | 0.371   | 8 (53)          | 7 (44)              | 0.715   |
| Deaths, no. (%)                        | First epidemic     | 39 (31)         | 0.101   | 2 (100)         | 1 (50)              | 1.000   |
|                                        | Second epidemic    | 120 (43)        | 0.578   | 2 (67)          | 1 (33)              | 1.000   |
|                                        | Third epidemic     | 94 (45)         | 1.000   | 1 (50)          | 1 (50)              | 1.000   |
|                                        | Fourth epidemic    | 45 (42)         | 0.639   | 1 (25)          | 1 (33)              | 1.000   |
|                                        | Fifth epidemic     | 272 (38)        | 0.156   | 3 (75)          | 1 (25)              | 0.486   |
| Total                                  | 570 (40)           | 9 (60)          | 0.119   | 9 (60)          | 5 (36)              | 0.272   |
| Hospitalization, no. (%)               | First epidemic     | 69/126 (55)     | 0.502   | 2 (100)         | 2 (100)             | –       |
|                                        | Second epidemic    | 221/282 (78)    | 1.000   | 3 (100)         | 3 (100)             | –       |
|                                        | Third epidemic     | 178/207 (86)    | 1.000   | 2 (100)         | 2 (100)             | –       |
|                                        | Fourth epidemic    | 84/106 (79)     | 0.582   | 4 (100)         | 3 (100)             | –       |
|                                        | Fifth epidemic     | 636/711 (89)    | 1.000   | 4 (100)         | 4 (100)             | –       |
| Total                                  | 1,188/1,432 (83)   | 15 (100)        | 0.090   | 15 (100)        | 14 (100)            | –       |
| ICU admission, no. (%)\*              | First epidemic     | 36/125 (29)     | 0.088   | 2 (100)         | 2 (100)             | –       |
|                                        | Second epidemic    | 131/282 (46)    | 0.103   | 3 (100)         | 2 (67)              | 1.000   |
### Characteristics

| Characteristics | Comparison of sporadic and cluster-associated index infections | Comparison of cluster-associated index and secondary infections with probable human-to-human transmission |
|-----------------|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
|                 | Sporadic infections | Index infections | $P$ value | Index infections | Secondary infections† | $P$ value |
| Total No. of infections |                           |                               |       |                           |                   |
| First epidemic  | 126                      | 2                             | –      | 2                          | 2                  | –      |
| Third epidemic  | 119/207 (57)            | 2 (100)                       | 0.510  | 2 (100)                    | 1 (50)             | 1.000  |
| Fourth epidemic | 58/106 (55)             | 2 (50)                        | 1.000  | 2 (50)                     | 1 (33)             | 1.000  |
| Fifth epidemic  | 443/693 (64)            | 4 (100)                       | 0.303  | 4 (100)                    | 2 (50)             | 0.429  |
| Total           | 787/1,413 (56)          | 13 (87)                       | **0.018** | 13 (87)                    | **8 (57)**         | 0.109  |
| Oseltamivir treatment, no. (%) |                   |                               |       |                           |                   |
| First epidemic  | 51/125 (41)             | 2 (100)                       | 0.172  | 2 (100)                    | 2 (100)            | –      |
| Second epidemic | 188/282 (67)            | 2 (67)                        | 1.000  | 2 (67)                     | 2 (67)             | 1.000  |
| Third epidemic  | 145/207 (70)            | 1 (50)                        | 0.513  | 1 (50)                     | 1 (50)             | 1.000  |
| Fourth epidemic | 67/106 (63)             | 4 (100)                       | 0.295  | 4 (100)                    | 2 (67)             | 0.429  |
| Fifth epidemic  | 543/694 (78)            | 4 (100)                       | 0.582  | 4 (100)                    | 4 (100)            | –      |
| Total           | 994/1,414 (70)          | 13 (87)                       | 0.255  | 13 (87)                    | 11 (79)            | 0.651  |
| Mechanical ventilation, no. (%) |                   |                               |       |                           |                   |
| First epidemic  | 28/125 (22)             | 1 (50)                        | 0.406  | 1 (50)                     | 1 (50)             | 1.000  |
| Second epidemic | 97/282 (34)             | 2 (67)                        | 0.277  | 2 (67)                     | 1 (33)             | 1.000  |
| Third epidemic  | 94/207 (45)             | 1 (50)                        | 1.000  | 1 (50)                     | 0                  | 1.000  |
| Fourth Epidemic | 41/106 (39)             | 2 (50)                        | 0.643  | 2 (50)                     | 0                  | 0.429  |
| Fifth epidemic  | 310/688 (45)            | 3 (75)                        | 0.333  | 3 (75)                     | 0                  | 0.143  |
| Total           | 570/1,408 (40)          | 9 (60)                        | 0.185  | 9 (60)                     | 2 (14)             | **0.021** |

*ICU denotes intensive care unit. Categorical variables were compared using Fisher exact test. Median age was compared using rank-sum Wilcoxon test. Boldface indicates significance; –, not applicable.

†Among 3 clusters comprised of 3 case-patients each, two clusters each had one case-patient with probable human-to-human transmission, and in the remaining cluster, the third case-patient had close contact with both of the other 2 case-patients before illness onset, so for this cluster, 2 case-patients are considered index cases in the analyses.
Technical Appendix Figure. Location of clusters of human infections with avian influenza A(H7N9) virus by province and epidemic in Mainland China, February 1, 2013 - June 30, 2017.